



#9

Petitioner's Docket No. MPI00-420P1R

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Meyers, Rachel E.
Application No.: 09/970,638 Group No.:
Filed: October 03, 2001 Examiner:
For: 27419, A NOVEL HUMAN ARGININE-N-METHYL TRANSFERASE
AND USES THEREOF

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 07 2002

REVOCATION OF PRIOR POWERS OF ATTORNEY
AND APPOINTMENT OF NEW POWER OF ATTORNEY

TECH CENTER 1600/2900

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document recorded with the United States Patent and Trademark Office on March 4 2002, at Reel 012681, Frame 0156 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"
Mailing Label No. _____

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature

Date 9-27-02

MARIAN CHRISTOPHER
(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10, without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.



Practitioner's Docket No. MPI00-420P1R

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

Scott A. Brown, Reg. No. 32,724; Susan M. Perkins, Reg. No. 36,405;
Jean M. Silveri, Reg. No. 39,030; Theodore R. Allen, Reg. No. 41,578;
Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 51,609;
and Steven A Bossone, Reg. No. 51,196;

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts
02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

and direct all telephone calls to Theodore R. Allen at 617-761-6815

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Typed Name: Scott A. Brown

Title: Vice President, Chief Patent Counsel

Dated: September 6, 2002



GP1645

OCT 03 2002

Please type a plus sign (+) inside this box → +

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

Application Number	09/970,638
Filing Date	October 3, 2001
First Named Inventor	Rachel MEYERS
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket No.	381552003900

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input checked="" type="checkbox"/> Revocation and Power of Attorney, Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	CUSTOMER NO. 25225	

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Carolyn A. Favorito, Reg. No. 39,183 MORRISON & FOERSTER LLP 3811 Valley Centre Drive, Suite 500, San Diego, California 92130-2332
Signature	
Date	September 27, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 27, 2002.

Marian Christopher

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.